Annual double-digit growth rates have been a regular feature of the Egyptian pharmaceuticals industry, and the country’s compelling demographic dividend offers some of the same benefits to producers as seen in other segments of the economy. However, in 2012 and likely into 2013, the outlook is more modest, as recent challenges since the political...